# Post Holdings, Inc.: financial statements, quarterly

POST · NYSE · CIK 1530950 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/post.md) · [Financials](/companies/post/financials.md) · [Filings](/companies/post/filings.md) · [Insiders](/companies/post/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/post/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,945 d](/filings/0001530950-25-000260.md) | [1,966](/filings/0001530950-25-000073.md) | [1,999](/filings/0001530950-25-000157.md) | [1,948](/filings/0001530950-25-000234.md) | [2,010 d](/filings/0001530950-25-000260.md) | [1,975](/filings/0001530950-26-000020.md) | [1,952](/filings/0001530950-26-000057.md) | [1,984](/filings/0001530950-26-000077.md) | [2,247 d](/filings/0001530950-25-000260.md) | [2,175](/filings/0001530950-26-000020.md) | [2,043](/filings/0001530950-26-000057.md) | [1,948](/filings/0001530950-26-000077.md) |
| Cost of revenue | $m | [1,394 d](/filings/0001530950-25-000260.md) | [1,393](/filings/0001530950-25-000073.md) | [1,419](/filings/0001530950-25-000157.md) | [1,370](/filings/0001530950-25-000234.md) | [1,435 d](/filings/0001530950-25-000260.md) | [1,379](/filings/0001530950-26-000020.md) | [1,406](/filings/0001530950-26-000057.md) | [1,388](/filings/0001530950-26-000077.md) | [1,645 d](/filings/0001530950-25-000260.md) | [1,536](/filings/0001530950-26-000020.md) | [1,425](/filings/0001530950-26-000057.md) | [1,382](/filings/0001530950-26-000077.md) |
| Gross profit | $m | [551 d](/filings/0001530950-25-000260.md) | [573](/filings/0001530950-25-000073.md) | [580](/filings/0001530950-25-000157.md) | [577](/filings/0001530950-25-000234.md) | [575 d](/filings/0001530950-25-000260.md) | [595](/filings/0001530950-26-000020.md) | [546](/filings/0001530950-26-000057.md) | [596](/filings/0001530950-26-000077.md) | [602 d](/filings/0001530950-25-000260.md) | [639](/filings/0001530950-26-000020.md) | [618](/filings/0001530950-26-000057.md) | [566](/filings/0001530950-26-000077.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [310 d](/filings/0001530950-25-000260.md) | [323](/filings/0001530950-25-000073.md) | [341](/filings/0001530950-25-000157.md) | [325](/filings/0001530950-25-000234.md) | [342 d](/filings/0001530950-25-000260.md) | [332](/filings/0001530950-26-000020.md) | [315](/filings/0001530950-26-000057.md) | [312](/filings/0001530950-26-000077.md) | [350 d](/filings/0001530950-25-000260.md) | [357](/filings/0001530950-26-000020.md) | [326](/filings/0001530950-26-000057.md) | [326](/filings/0001530950-26-000077.md) |
| Operating income | $m | [153 d](/filings/0001530950-25-000260.md) | [209](/filings/0001530950-25-000073.md) | [190](/filings/0001530950-25-000157.md) | [203](/filings/0001530950-25-000234.md) | [191 d](/filings/0001530950-25-000260.md) | [214](/filings/0001530950-26-000020.md) | [182](/filings/0001530950-26-000057.md) | [235](/filings/0001530950-26-000077.md) | [168 d](/filings/0001530950-25-000260.md) | [238](/filings/0001530950-26-000020.md) | [212](/filings/0001530950-26-000057.md) | [189](/filings/0001530950-26-000077.md) |
| Interest expense | $m | [76.7 d](/filings/0001530950-25-000260.md) | [78.1](/filings/0001530950-25-000073.md) | [80.0](/filings/0001530950-25-000157.md) | [78.8](/filings/0001530950-25-000234.md) | [79.6 d](/filings/0001530950-25-000260.md) | [84.1](/filings/0001530950-26-000020.md) | [87.0](/filings/0001530950-26-000057.md) | [88.5](/filings/0001530950-26-000077.md) | [102 d](/filings/0001530950-25-000260.md) | [103](/filings/0001530950-26-000020.md) | [106](/filings/0001530950-26-000057.md) | [108](/filings/0001530950-26-000077.md) |
| Income tax | $m | [29.3 d](/filings/0001530950-25-000260.md) | [28.5](/filings/0001530950-25-000073.md) | [28.6](/filings/0001530950-25-000157.md) | [31.7](/filings/0001530950-25-000234.md) | [16.3 d](/filings/0001530950-25-000260.md) | [32.1](/filings/0001530950-26-000020.md) | [20.0](/filings/0001530950-26-000057.md) | [34.7](/filings/0001530950-26-000077.md) | [21.9 d](/filings/0001530950-25-000260.md) | [27.3](/filings/0001530950-26-000020.md) | [28.1](/filings/0001530950-26-000057.md) | [23.1](/filings/0001530950-26-000077.md) |
| Net income | $m | [65.7 d](/filings/0001530950-25-000260.md) | [88.1](/filings/0001530950-25-000073.md) | [97.2](/filings/0001530950-25-000157.md) | [99.8](/filings/0001530950-25-000234.md) | [81.6 d](/filings/0001530950-25-000260.md) | [113](/filings/0001530950-26-000020.md) | [62.6](/filings/0001530950-26-000057.md) | [109](/filings/0001530950-26-000077.md) | [51.0 d](/filings/0001530950-25-000260.md) | [96.8](/filings/0001530950-26-000020.md) | [81.9](/filings/0001530950-26-000057.md) | [63.4](/filings/0001530950-26-000077.md) |
| Diluted EPS | $ per share | not reported | [1.35](/filings/0001530950-25-000073.md) | [1.48](/filings/0001530950-25-000157.md) | [1.53](/filings/0001530950-25-000234.md) | not reported | [1.78](/filings/0001530950-26-000020.md) | [1.03](/filings/0001530950-26-000057.md) | [1.79](/filings/0001530950-26-000077.md) | not reported | [1.71](/filings/0001530950-26-000020.md) | [1.56](/filings/0001530950-26-000057.md) | [1.29](/filings/0001530950-26-000077.md) |
| Basic EPS | $ per share | not reported | [1.46](/filings/0001530950-25-000073.md) | [1.60](/filings/0001530950-25-000157.md) | [1.66](/filings/0001530950-25-000234.md) | not reported | [1.94](/filings/0001530950-26-000020.md) | [1.11](/filings/0001530950-26-000057.md) | [1.95](/filings/0001530950-26-000077.md) | not reported | [1.87](/filings/0001530950-26-000020.md) | [1.71](/filings/0001530950-26-000057.md) | [1.41](/filings/0001530950-26-000077.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.1](/filings/0001530950-24-000365.md) | [0.2](/filings/0001530950-24-000054.md) | [0.3](/filings/0001530950-24-000144.md) | [0.3](/filings/0001530950-24-000223.md) | [0.8](/filings/0001530950-25-000260.md) | [0.9](/filings/0001530950-25-000073.md) | [0.6](/filings/0001530950-25-000157.md) | [1.1](/filings/0001530950-25-000234.md) | [0.2](/filings/0001530950-26-000077.md) | [0.3](/filings/0001530950-26-000020.md) | [0.3](/filings/0001530950-26-000057.md) | [0.3](/filings/0001530950-26-000077.md) |
| Current assets | $bn | [1.5](/filings/0001530950-24-000365.md) | [1.7](/filings/0001530950-24-000054.md) | [1.8](/filings/0001530950-24-000144.md) | [1.8](/filings/0001530950-24-000223.md) | [2.2](/filings/0001530950-25-000260.md) | [2.3](/filings/0001530950-25-000073.md) | [2.2](/filings/0001530950-25-000157.md) | [2.6](/filings/0001530950-25-000234.md) | [2.0](/filings/0001530950-26-000077.md) | [2.0](/filings/0001530950-26-000020.md) | [2.1](/filings/0001530950-26-000057.md) | [2.0](/filings/0001530950-26-000077.md) |
| Total assets | $bn | [11.6](/filings/0001530950-25-000260.md) | [12.1](/filings/0001530950-24-000054.md) | [12.2](/filings/0001530950-24-000144.md) | [12.1](/filings/0001530950-24-000223.md) | [12.9](/filings/0001530950-25-000260.md) | [12.8](/filings/0001530950-25-000073.md) | [12.8](/filings/0001530950-25-000157.md) | [13.4](/filings/0001530950-25-000234.md) | [13.5](/filings/0001530950-26-000077.md) | [13.0](/filings/0001530950-26-000020.md) | [13.0](/filings/0001530950-26-000057.md) | [12.9](/filings/0001530950-26-000077.md) |
| Current liabilities | $bn | [0.8](/filings/0001530950-24-000365.md) | [0.8](/filings/0001530950-24-000054.md) | [0.8](/filings/0001530950-24-000144.md) | [0.9](/filings/0001530950-24-000223.md) | [0.9](/filings/0001530950-25-000260.md) | [1.0](/filings/0001530950-25-000073.md) | [1.0](/filings/0001530950-25-000157.md) | [1.0](/filings/0001530950-25-000234.md) | [1.2](/filings/0001530950-26-000077.md) | [1.0](/filings/0001530950-26-000020.md) | [1.1](/filings/0001530950-26-000057.md) | [1.1](/filings/0001530950-26-000077.md) |
| Total liabilities | $bn | [7.8](/filings/0001530950-24-000365.md) | [8.1](/filings/0001530950-24-000054.md) | [8.2](/filings/0001530950-24-000144.md) | [8.2](/filings/0001530950-24-000223.md) | [8.8](/filings/0001530950-25-000260.md) | [8.9](/filings/0001530950-25-000073.md) | [9.0](/filings/0001530950-25-000157.md) | [9.4](/filings/0001530950-25-000234.md) | [9.8](/filings/0001530950-26-000077.md) | [9.5](/filings/0001530950-26-000020.md) | [9.8](/filings/0001530950-26-000057.md) | [9.8](/filings/0001530950-26-000077.md) |
| Long-term debt | $bn | [6.0](/filings/0001530950-24-000365.md) | [6.3](/filings/0001530950-24-000054.md) | [6.4](/filings/0001530950-24-000144.md) | [6.4](/filings/0001530950-24-000223.md) | [6.8](/filings/0001530950-25-000260.md) | [6.9](/filings/0001530950-25-000073.md) | [6.9](/filings/0001530950-25-000157.md) | [7.3](/filings/0001530950-25-000234.md) | [7.4](/filings/0001530950-26-000077.md) | [7.5](/filings/0001530950-26-000020.md) | [7.6](/filings/0001530950-26-000057.md) | [7.6](/filings/0001530950-26-000077.md) |
| Current portion of debt | $bn | [0.0](/filings/0001530950-24-000365.md) | [0.0](/filings/0001530950-24-000054.md) | [0.0](/filings/0001530950-24-000144.md) | [0.0](/filings/0001530950-24-000223.md) | [0.0](/filings/0001530950-25-000260.md) | [0.0](/filings/0001530950-25-000073.md) | [0.0](/filings/0001530950-25-000157.md) | [0.0](/filings/0001530950-25-000234.md) | [0.0](/filings/0001530950-26-000077.md) | [0.0](/filings/0001530950-26-000020.md) | [0.0](/filings/0001530950-26-000057.md) | [0.0](/filings/0001530950-26-000077.md) |
| Shareholders' equity | $bn | [3.8](/filings/0001530950-24-000365.md) | [3.9](/filings/0001530950-25-000073.md) | [4.0](/filings/0001530950-25-000157.md) | [3.9](/filings/0001530950-25-000234.md) | [4.1](/filings/0001530950-25-000260.md) | [3.9](/filings/0001530950-26-000020.md) | [3.8](/filings/0001530950-26-000057.md) | [4.0](/filings/0001530950-26-000077.md) | [3.8](/filings/0001530950-26-000077.md) | [3.5](/filings/0001530950-26-000020.md) | [3.2](/filings/0001530950-26-000057.md) | [3.1](/filings/0001530950-26-000077.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [270 d](/filings/0001530950-25-000260.md) | [174](/filings/0001530950-25-000073.md) | [250 d](/filings/0001530950-25-000157.md) | [272 d](/filings/0001530950-25-000234.md) | [235 d](/filings/0001530950-25-000260.md) | [310](/filings/0001530950-26-000020.md) | [161 d](/filings/0001530950-26-000057.md) | [226 d](/filings/0001530950-26-000077.md) | [301 d](/filings/0001530950-25-000260.md) | [236](/filings/0001530950-26-000020.md) | [242 d](/filings/0001530950-26-000057.md) | [213 d](/filings/0001530950-26-000077.md) |
| Capital expenditure | $m | [101 d](/filings/0001530950-25-000260.md) | [80.8](/filings/0001530950-25-000073.md) | [98.7 d](/filings/0001530950-25-000157.md) | [111 d](/filings/0001530950-25-000234.md) | [139 d](/filings/0001530950-25-000260.md) | [139](/filings/0001530950-26-000020.md) | [90.5 d](/filings/0001530950-26-000057.md) | [131 d](/filings/0001530950-26-000077.md) | [150 d](/filings/0001530950-25-000260.md) | [116](/filings/0001530950-26-000020.md) | [91.3 d](/filings/0001530950-26-000057.md) | [82.1 d](/filings/0001530950-26-000077.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.8](/filings/0001530950-24-000054.md) | [65.7](/filings/0001530950-24-000144.md) | [68.5](/filings/0001530950-24-000223.md) | [67.3](/filings/0001530950-25-000073.md) | [67.6](/filings/0001530950-25-000157.md) | [67.0](/filings/0001530950-25-000234.md) | [65.2](/filings/0001530950-26-000020.md) | [63.1](/filings/0001530950-26-000057.md) | [62.4](/filings/0001530950-26-000077.md) | [58.2](/filings/0001530950-26-000020.md) | [54.1](/filings/0001530950-26-000057.md) | [51.3](/filings/0001530950-26-000077.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,956,805 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001530950-26-000077.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.